Neurogene (NasdaqGM:NGNE) FY Conference Transcript

Neurogene FY Conference Summary Company Overview - Company: Neurogene (NasdaqGM:NGNE) - Focus: Development of genetic medicines for neurological diseases, specifically targeting Rett syndrome with their lead program NGN-401 [1][2] Core Points and Arguments Rett Syndrome and Market Opportunity - Rett syndrome is a severe neurological disorder primarily affecting girls, with an estimated 15,000-20,000 patients in the U.S. and Europe, representing a multi-billion dollar market opportunity for genetic treatments [3] - The company is actively progressing towards the commercialization of NGN-401, with ongoing Phase 3 trial (Embolden) enrollment expected to complete in Q2 2026 [3][4] EXACT Platform - The EXACT platform is designed to control gene expression levels, specifically the MECP2 transgene, which is crucial for preventing Rett syndrome [5][6] - The platform includes a microRNA-based safety valve to regulate transgene expression, avoiding toxic levels [6] Breakthrough Therapy Designation - Neurogene received Breakthrough Therapy designation from the FDA based on encouraging Phase 1-2 trial results, including new patient-level data and video evidence demonstrating skill gains [4][8][9] Clinical Trial Insights - The primary endpoint of the Embolden trial includes video-based documentation of skill gains and developmental milestones [16] - The Phase 1-2 trial showed a time-dependent improvement in function, with patients gaining skills over time rather than just stabilizing [18][27] - The trial has reported an increase in developmental milestones from 23 to 35 across 8 patients, indicating a deepening effect over time [61][172] Safety and Monitoring - The company has implemented safety protocols, including monitoring for HLH (Hemophagocytic Lymphohistiocytosis), which was previously observed at higher doses but has not occurred at current dosing levels [180][185] - No cases of HLH have been reported in the ongoing trials, indicating effective safety measures [185] Regulatory Considerations - Neurogene emphasizes the importance of a 12-month primary endpoint for the Embolden study, arguing that the FDA and caregivers prefer more data for assessing long-term benefits [192] - The company believes that a 12-month assessment is necessary for understanding the benefit-risk profile of gene therapies for Rett syndrome [192] Other Important Content - The company is focused on establishing a commercialization pathway and engaging with payers to support the launch of NGN-401 [4] - The commitment of families involved in the trial is highlighted, as they are already engaged in physical and occupational therapies to maximize outcomes for their children [95] - The company is optimistic about the long-term data from the trial, which will be valuable for various stakeholders, including caregivers, payers, and regulators [112][188] This summary encapsulates the key points discussed during the Neurogene FY Conference, focusing on the company's advancements in gene therapy for Rett syndrome, the significance of their EXACT platform, and the ongoing clinical trials.